Comparative Pharmacology
Head-to-head clinical analysis: ISRADIPINE versus TAZTIA XT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISRADIPINE versus TAZTIA XT.
ISRADIPINE vs TAZTIA XT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary arteries and peripheral arterioles, and reduction of myocardial contractility and heart rate.
2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.
Oral, 120 mg or 180 mg once daily. For hypertension, initiate at 120 mg once daily; for angina, initiate at 180 mg once daily. Maximum dose: 360 mg once daily.
None Documented
None Documented
Clinical Note
moderateIsradipine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid."
Clinical Note
moderateIsradipine + Furosemide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide."
Clinical Note
moderateIsradipine + Bumetanide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide."
Clinical Note
moderateIsradipine + Travoprost
Terminal elimination half-life 8 hours (range 6-12 hours); clinical context: supports twice-daily dosing, requires dose adjustment in hepatic impairment.
3-5 hours (immediate-release) for diltiazem; after TAZTIA XT extended-release, effective half-life is approximately 7-9 hours due to prolonged absorption. Clinical context: steady state achieved in 3-5 days.
Renal: 65% (as metabolites, <1% unchanged); Fecal: 35% (biliary elimination); total clearance 1.4 L/min.
Renal (approximately 60% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion), biliary/fecal (approximately 30-35%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker
"Isradipine may increase the hypotensive activities of Travoprost."